CIT_GAP-Funds_logo

CIT GAP Funds Portfolio Company, TypeZero Technologies, Acquired by Dexcom

Charlottesville startup with U.Va. roots continues to improve and simplify the lives of people with diabetes through integrated technology

September 6, 2018 – The Center for Innovative Technology (CIT) is proud to announce that its CIT GAP Funds portfolio company, TypeZero Technologies, Inc. was acquired by Dexcom, Inc., the leader in continuous glucose monitoring for people with diabetes. In 2015, CIT GAP Funds led TypeZero’s seed round, furthering the development of the startup’s diabetes management technology that was licensed from the University of Virginia. TypeZero will continue operations out of Virginia as they enhance and accelerate Dexcom’s offering with tools to simplify diabetes management. 

TypeZero leverages more than 10 years of clinical trials, research and innovation to develop their proprietary inControl Diabetes Management Platform with the goal of improving the lives of people with diabetes, and supporting healthcare providers to make more informed decisions. To address the challenge of effectively managing diabetes in a safe and simple way, TypeZero’s inControl platform includes advisory applications for smart insulin pens and smartphone-based systems that automatically regulate insulin delivery to reduce hypoglycemia and improve blood glucose levels.  

“Since our seed investment back in 2015, TypeZero has continued to prove themselves as a leader in this field and a valuable innovator in the Commonwealth of Virginia,” said Tom Weithman, Managing Director of CIT GAP Funds.  “TypeZero is offering patients a huge advantage in the management of their diabetes by integrating treatment solutions into the technology they are already using.”  TypeZero’s software platform transforms the patient’s role in managing his or her blood glucose from hour-to-hour, active decision making and modification, to periodic supervision of a trustworthy, automated, intelligent system. TypeZero has also developed a suite of cloud-based applications and analytical services, which utilize its core algorithms to provide risk analysis, prediction, and clinical recommendations.

“The inControl system allows users to spend less time managing their diabetes, and more time living their life. We are excited to join Dexcom’s portfolio and expand on our shared mission of empowering people with diabetes through innovation,” said Chad Rogers, CEO of TypeZero. “CIT’s early support of TypeZero played an important role in the company reaching this next chapter, and we look forward to sharing this journey with our Virginia network as we continue to grow and reduce significant burdens that many people with diabetes face.”

CIT GAP Funds, a family of funds placing equity investments in Virginia-based technology, life science, and cleantech companies, has invested in over 200 high-potential, early-stage companies likely to achieve rapid growth and generate significant economic return. Since it’s 2005 formation, CIT GAP Funds has infused an additional $600M+ of private placements onto the balance sheets of portfolio companies. Funds have come from over 900 different investment sources, with 80 percent including out-of-state and blue-chip funding sources from across the U.S. For more information, please visit www.cit.org.  For more information on TypeZero, please visit www.typezero.com.

About CIT GAP Funds
CIT GAP Funds makes seed-stage equity investments in Virginia-based technology, clean tech and life science companies with a high potential for achieving rapid growth and generating significant economic return for entrepreneurs, co-investors and the Commonwealth of Virginia. CIT GAP Funds’ investments are overseen by the CIT GAP Funds Investment Advisory Board (IAB). This independent, third-party panel consists of leading regional entrepreneurs, angel and strategic investors, and venture capital firms such as New Enterprise Associates, Grotech Ventures, Valhalla Partners, Harbert Venture Partners HIG Ventures, Edison Ventures, In-Q-Tel, Intersouth Partners, SJF Ventures, Carilion Health Systems, Johnson & Johnson, General Electric, and Alpha Natural Resources. For more information, please visit www.citgapfunds.org.

 



CIT GAP Funds Invests in Embody

Advancing the Treatment of Tendon and Ligament Injuries for Warfighters and Sports Medicine Patients

August 28, 2018 – The Center for Innovative Technology (CIT) announced today that CIT GAP Funds has invested in Embody, a Norfolk, Virginia based medical device company developing collagen-based products for the treatment of tendon and ligament injuries. The 757 Angels led this investment in Embody’s convertible debt round, alongside CIT and individual investors.

Over two million patients are affected by soft tissue injuries annually in the United States. Embody’s mission is to improve the standard of care for these traumatic and sports injury patients by providing products that promote faster healing and restore pre-injury performance. Embody has been funded with $12 million from the Defense Advanced Research Projects Agency (DARPA) based on the need to advance the treatment standards for warfighters and veterans.

“Embody is creating a new standard of care for sports medicine patients by leveraging biomaterials and advanced manufacturing technologies to create products to accelerate rehabilitation,” said Jeff Conroy, CEO of Embody. “Thanks to the support of CIT and 757 Angels, we will launch our first product following FDA 510(k) clearance in 2019. 757 Angels is a major catalyst of entrepreneurship in the Hampton Roads region and has been critical to the success of Embody.”

“Biotechnology, specifically the area of regenerative medicine, deserves a spotlight in 2018,” said Thomas Weithman, Managing Director of CIT GAP Funds and Chief Investment Officer at MACH37. “This industry is ripe with innovation that has the potential to significantly improve the lives of patients. We were drawn to the experience of the Embody team and their strong relationships with DARPA, the University of Virginia, Old Dominion University, Virginia’s CATALYST and 757 Angels. ”

Together with partners, CIT GAP Funds is able to provide an expanded pool of investment opportunities and capital support services than might otherwise not be available to targeted companies. Co-investing in Embody with 757 Angels, who, like CIT aims to grow and diversify the economy by supporting promising new and early stage companies, paves the way for future collaboration and supports regionally-based innovation initiatives such as increased investment opportunities for Virginia-based entrepreneurs traditionally underrepresented in venture capital.

Monique Sury Adams, Executive Director of 757 Angels, adds, “Virginia had one of the slowest growth rates in the country back in 2013, and our mission is to develop implementable initiatives that lead to a stronger and more supportive entrepreneurial environment. Working with CIT is a great opportunity to help more entrepreneurs build their business based on tried and true strategies and sound investments, and continue to grow business in the Hampton Roads area. 757 Angels is proud to add Embody to our list of investments!”

CIT GAP Funds, a family of funds placing equity investments in Virginia-based technology, life science, and cleantech companies, has invested in over 200 high-potential, early-stage companies likely to achieve rapid growth and generate significant economic return. Since it’s 2005 formation, CIT GAP Funds has infused an additional $600M+ of private placements onto the balance sheets of portfolio companies. Funds have come from over 900 different investment sources, with 80 percent including out-of-state and blue-chip funding sources from across the U.S. For more information, please visit https://www.cit.org/.


About Embody
Embody LLC is a medical device company focused on the development of implantable medical devices to treat significant tendon and ligament injuries. With the support of DARPA and leveraging our expertise in biomaterials and advance manufacturing, we are engineering implantable devices that will significantly improve patient outcomes following tendon and ligament injury. More information is available at https://embodyparts.com/.

About 757 Angels
757 Angels seeks to provide risk adjusted returns for its members and investors and to catalyze the economy. 757 Angels is a select network of over 100 business and community leaders in the Hampton Roads region, who provide investment capital, strategic advice and mentoring to selected startup and early stage companies to help them achieve market leadership. 757 Angels seeks dealflow from the Commonwealth of Virginia. For more information, visit https://www.757angelsgroup.com/.

About CIT GAP Funds
CIT GAP Funds makes seed-stage equity investments in Virginia-based technology, clean tech and life science companies with a high potential for achieving rapid growth and generating significant economic return for entrepreneurs, co-investors and the Commonwealth of Virginia. CIT GAP Funds’ investments are overseen by the CIT GAP Funds Investment Advisory Board (IAB). This independent, third-party panel consists of leading regional entrepreneurs, angel and strategic investors, and venture capital firms such as New Enterprise Associates, Grotech Ventures, Valhalla Partners, Harbert Venture Partners HIG Ventures, Edison Ventures, In-Q-Tel, Intersouth Partners, SJF Ventures, Carilion Health Systems, Johnson & Johnson, General Electric, and Alpha Natural Resources. For more information, please visit www.citgapfunds.org